TNFRSF4 and neuroblastoma: In terms of clinical outcomes, we observed that Low expression of TNFRSF4 significantly reduced survival probabilities in neuroblastoma in the SEQC cohort of 498 neuroblastomas in terms of both OS (p = 1.53e-09) and EFS (p = 4.2e-04) (Fig 4A and 4B).